Progress in characterization, preparation and clinical applications of non-hematopoietic stem cells, 29-30 September 2006, Tübingen, Germany.

Progress in characterization, preparation and clinical applications of non-hematopoietic stem cells, 29 30 September 2006, Tubingen, Germany R Schafer, M Dominici, I Muller, F Dazzi, K Bieback, K Godthardt, K Le Blanc, R Meisel, R Pochampally, R Richter, T Skutella, G Steinhoff, M Mitterberger, HP Wendel, J Wiskirchen, R Handgretinger and H Northoff Institute of Clinical and Experimental Transfusion Medicine, University Hospital Tubingen, Germany, Laboratory of Cell Biology and Advanced Cancer Therapies, Department of Oncology and Haematology, University of Modena and Reggio Emilia, Modena, Italy, Department of Paediatric Haematology Oncology, University Hospital Tubingen, Germany, Stem Cell Biology Section, Kennedy Institute of Reumatology and Investigative Science Division, Imperial College, Hammersmith Campus, London, UK, Institute of Transfusion Medicine and Immunohaematology Mannheim, German Red Cross Blood Service, Faculty of Clinical Medicine Mannheim University Heidelberg, Germany, Miltenyi Biotec, Bergisch-Gladbach, Germany, Center for Allogeneic Stem Cell Transplantation, Karolinska University Hospital, Stockholm, Sweden, Department of Paediatric Haematology Oncology, University Hospital Duesseldorf, Germany, Tulane University Health Science Center, New Orleans, USA, Institute of Transfusion Medicine and Immunohaematology Frankfurt/Main, German Red Cross Blood Service, University of Frankfurt/Main, Germany, Institute of Anatomy, Department of Anatomy and Embryology, University of Tubingen, Germany, Clinic and Policlinic of Heart Surgery, University Hospital of Rostock, Germany, Department of Urology, University Hospital Innsbruck/Austria, Department of Thoracic, Cardiac and Vascular Surgery, University Hospital Tubingen, Germany, and Department of Diagnostic Radiology, University Hospital Tubingen, Germany

[1]  E. Lam,et al.  Mesenchymal stem cells inhibit proliferation and apoptosis of tumor cells: impact on in vivo tumor growth , 2007, Leukemia.

[2]  I. Krägeloh-Mann,et al.  In vitro analysis of multipotent mesenchymal stromal cells as potential cellular therapeutics in neurometabolic diseases in pediatric patients. , 2006, Experimental hematology.

[3]  Gerhard Ziemer,et al.  A New Technique for the Isolation and Surface Immobilization of Mesenchymal Stem Cells from Whole Bone Marrow Using High‐Specific DNA Aptamers , 2006, Stem cells.

[4]  S. Nadri,et al.  Murine mesenchymal stem cells isolated by low density primary culture system , 2006, Development, growth & differentiation.

[5]  R. Brenner,et al.  Mesenchymal Progenitor Cells Communicate via Alpha and Beta Integrins with a Three-Dimensional Collagen Type I Matrix , 2006, Cells Tissues Organs.

[6]  C. D. Claussen,et al.  Effect of Concentration of SH U 555A Labeled Human Melanoma Cells on MR Spin Echo and Gradient Echo Signal Decay at 0.2, 1.5, and 3T , 2006, Magnetic Resonance Materials in Physics, Biology and Medicine.

[7]  R. Ramasamy,et al.  The role of mesenchymal stem cells in haemopoiesis. , 2006, Blood reviews.

[8]  L. Zangi,et al.  Isolation of mesenchymal stem cells from G-CSF-mobilized human peripheral blood using fibrin microbeads , 2006, Bone Marrow Transplantation.

[9]  Sergio Romagnani,et al.  Role for Interferon‐γ in the Immunomodulatory Activity of Human Bone Marrow Mesenchymal Stem Cells , 2006 .

[10]  R. Handgretinger,et al.  Animal serum-free culture conditions for isolation and expansion of multipotent mesenchymal stromal cells from human BM. , 2006, Cytotherapy.

[11]  D. Prockop,et al.  Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. , 2006, Cytotherapy.

[12]  P. Behrens,et al.  In vivo matrix-guided human mesenchymal stem cells , 2006, Cellular and Molecular Life Sciences.

[13]  S. Rafii,et al.  VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche , 2005, Nature.

[14]  M. Richard,et al.  Mesenchymal stem cells induce apoptosis of activated T cells , 2005, Leukemia.

[15]  G. Mancardi,et al.  Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. , 2005, Blood.

[16]  C D Claussen,et al.  Eine Präparationstechnik zur quantitativen Untersuchung SPIO-haltiger Lösungen und SPIO-markierter Zellen in der MRT / A preparation technique for quantitative investigation of SPIO-containing solutions and SPIO-labelled cells by MRI , 2005, Biomedizinische Technik. Biomedical engineering.

[17]  E. Lam,et al.  Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. , 2005, Blood.

[18]  H. Kalervo Väänänen.  Mesenchymal stem cells , 2005 .

[19]  M. Kotb,et al.  Human Lymphoid and Myeloid Cell Development in NOD/LtSz-scid IL2Rγnull Mice Engrafted with Mobilized Human Hemopoietic Stem Cells 12 , 2004, The Journal of Immunology.

[20]  E. Rummeny,et al.  Migration of iron oxide-labeled human hematopoietic progenitor cells in a mouse model: in vivo monitoring with 1.5-T MR imaging equipment. , 2005, Radiology.

[21]  Jeff W M Bulte,et al.  Chondrogenic differentiation of mesenchymal stem cells is inhibited after magnetic labeling with ferumoxides. , 2004, Blood.

[22]  R. Pochampally,et al.  Isolation of a Highly Clonogenic and Multipotential Subfraction of Adult Stem Cells from Bone Marrow Stroma , 2004, Stem cells.

[23]  D. Persons,et al.  Hematopoietic cells and osteoblasts are derived from a common marrow progenitor after bone marrow transplantation. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[24]  Ernst J. Rummeny,et al.  Capacity of human monocytes to phagocytose approved iron oxide MR contrast agents in vitro , 2004, European Radiology.

[25]  Ulrich Göbel,et al.  bloodjournal.hematologylibrary.org at PENN STATE UNIVERSITY on February 20, 2013. For personal use , 2004 .

[26]  Ernst J. Rummeny,et al.  Cell tracking with gadophrin-2: a bifunctional contrast agent for MR imaging, optical imaging, and fluorescence microscopy , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[27]  Moustapha Hassan,et al.  Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells , 2004, The Lancet.

[28]  T. Brümmendorf,et al.  CDCP1 Identifies a Broad Spectrum of Normal and Malignant Stem/Progenitor Cell Subsets of Hematopoietic and Nonhematopoietic Origin , 2004, Stem cells.

[29]  B. Larson,et al.  Adult stem cells from bone marrow (MSCs) isolated from different strains of inbred mice vary in surface epitopes, rates of proliferation, and differentiation potential. , 2004, Blood.

[30]  S. Mackinnon,et al.  Immune reconstitution following haematopoietic stem cell transplantation , 2004, British journal of haematology.

[31]  Elliot R. McVeigh,et al.  Magnetic Resonance Fluoroscopy Allows Targeted Delivery of Mesenchymal Stem Cells to Infarct Borders in Swine , 2003, Circulation.

[32]  E. Unger.  How can superparamagnetic iron oxides be used to monitor disease and treatment? , 2003, Radiology.

[33]  Haiyang Huang,et al.  Identification of the haematopoietic stem cell niche and control of the niche size , 2003, Nature.

[34]  C. Uyttenhove,et al.  Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase , 2003, Nature Medicine.

[35]  Bing Liu,et al.  Isolation of Mouse Marrow Mesenchymal Progenitors by a Novel and Reliable Method , 2003, Stem cells.

[36]  C. Fathman,et al.  CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation , 2003, Nature Medicine.

[37]  Jeff W M Bulte,et al.  Clinically applicable labeling of mammalian and stem cells by combining superparamagnetic iron oxides and transfection agents. , 2003, Radiology.

[38]  L. Kanz,et al.  Antibody W7C5 Defines a CD109 Epitope Expressed on CD34+ and CD34− Hematopoietic and Mesenchymal Stem Cell Subsets , 2003, Annals of the New York Academy of Sciences.

[39]  Ralph Weissleder,et al.  Near-infrared optical imaging of proteases in cancer. , 2003, Molecular cancer therapeutics.

[40]  Elizabeth Simpson,et al.  Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. , 2003, Blood.

[41]  G. Seitz,et al.  Identification of a novel class of human adherent CD34- stem cells that give rise to SCID-repopulating cells. , 2003, Blood.

[42]  Mathias Hoehn,et al.  Monitoring of implanted stem cell migration in vivo: A highly resolved in vivo magnetic resonance imaging investigation of experimental stroke in rat , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[43]  Scott E. Fraser,et al.  Tracking Transplanted Stem Cell Migration Using Bifunctional, Contrast Agent-Enhanced, Magnetic Resonance Imaging , 2002, NeuroImage.

[44]  L. Muul,et al.  Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[45]  C. Carlo-Stella,et al.  Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. , 2002, Blood.

[46]  Kevin McIntosh,et al.  Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. , 2002, Experimental hematology.

[47]  Peter van Gelderen,et al.  Magnetodendrimers allow endosomal magnetic labeling and in vivo tracking of stem cells , 2001, Nature Biotechnology.

[48]  J. Zaia,et al.  The SH-3 and SH-4 antibodies recognize distinct epitopes on CD73 from human mesenchymal stem cells. , 2001, Biochemical and biophysical research communications.

[49]  S A Wickline,et al.  Novel MRI Contrast Agent for Molecular Imaging of Fibrin: Implications for Detecting Vulnerable Plaques , 2001, Circulation.

[50]  D J Prockop,et al.  Identification of a subpopulation of rapidly self-renewing and multipotential adult stem cells in colonies of human marrow stromal cells , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[51]  M. V. D. van den Brink,et al.  Differential use of Fas ligand and perforin cytotoxic pathways by donor T cells in graft-versus-host disease and graft-versus-leukemia effect. , 2001, Blood.

[52]  D. Piwnica-Worms,et al.  Beyond the Genome: Molecular Imaging in Vivo with PET and SPECT☆ , 2001 .

[53]  D. Piwnica-Worms,et al.  Molecular imaging in vivo with PET and SPECT. , 2001, Academic radiology.

[54]  J. Zaia,et al.  The monoclonal antibody SH-2, raised against human mesenchymal stem cells, recognizes an epitope on endoglin (CD105). , 1999, Biochemical and biophysical research communications.

[55]  M. Pittenger,et al.  Multilineage potential of adult human mesenchymal stem cells. , 1999, Science.

[56]  Darwin J. Prockop,et al.  Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta , 1999, Nature Medicine.

[57]  D. Munn,et al.  Prevention of allogeneic fetal rejection by tryptophan catabolism. , 1998, Science.

[58]  R. Jain,et al.  Intracellular magnetic labeling of lymphocytes for in vivo trafficking studies. , 1998, BioTechniques.

[59]  R E Jacobs,et al.  Fluorescently detectable magnetic resonance imaging agents. , 1998, Bioconjugate chemistry.

[60]  Chien Ho,et al.  In Vivo Dynamic MRI Tracking of Rat T‐Cells Labeled with Superparamagnetic Iron‐Oxide Particles , 1995, Magnetic resonance in medicine.

[61]  R. Weissleder,et al.  Receptor imaging: application to MR imaging of liver cancer. , 1990, Radiology.

[62]  R. Hoffmann,et al.  Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. , 1988 .

[63]  N. Kulagina,et al.  Fibroblast precursors in normal and irradiated mouse hematopoietic organs. , 1976, Experimental hematology.